All In Biotech

Drug Trial Radar · NCT05161390

Study of LM-302 in Patients With Advance Solid Tumors

A Phase I/II , Open, Multicentre, Dose-escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumour Activity of LM-302 in Patients With CLDN18.2 Positive Advanced Solid Tumours

Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

153

Actual

Start

Nov 26, 2021

Primary completion

Jan 10, 2025

Study completion Jan 10, 2025

Sponsor

Sponsor type
Industry
First posted
Dec 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I/II Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors

Conditions

  • Advanced Solid Tumor

Interventions

  • LM-302 InjectionDrug

    LM-302 Injection with dose escalation stage of different dose levels, as well as dose expansion stage with recommended dose level from dose escalation stage.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT)Time frame: Cycle 1 of each cohort. Duration of one cycle is 21 days
  2. Adverse Events and Serious Adverse EventsTime frame: From signing the ICF until 28 days after EOT or accept other anti-cancer therapy
  3. Recommended Phase II Dose (RP2D)Time frame: up to 21 days following first dose
  4. Maximum Tolerated Dose (MTD)Time frame: up to 21 days following first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.